List of Excipients in Branded Drug GOOD SENSE CLEARLAX

Generic Drugs Containing GOOD SENSE CLEARLAX

Company	Ingredient	NDC	Excipient
L Perrigo Company	polyethylene glycol 3350	0113-1023	SUCRALOSE

What are the Most Frequently-Used Excipients in GOOD SENSE CLEARLAX?

# Of NDCs	Excipient
1	SUCRALOSE

Good Sense ClearLax Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Good Sense ClearLax is an over-the-counter polyethylene glycol 3350 laxative powder. Its commercial position depends less on proprietary excipients and more on low-cost powder processing, rapid dissolution, palatability, packaging, retailer distribution, and compliance with the FDA OTC laxative framework. The formulation has limited patent protection and low technical entry barriers, but brand differentiation remains possible through flavor systems, stick packs, pediatric convenience, sustainability, and combination gastrointestinal products.

What is Good Sense ClearLax?

Good Sense ClearLax is a polyethylene glycol 3350, or PEG 3350, osmotic laxative. The labeled adult dose is generally 17 grams dissolved in 4 to 8 ounces of beverage and taken once daily for occasional constipation.[1]

Product attribute	Good Sense ClearLax profile
Active ingredient	Polyethylene glycol 3350
Dosage form	Oral powder for solution
Primary indication	Occasional constipation
Typical adult dose	17 g once daily
Administration	Dissolved in beverage
Pharmacology	Osmotic laxative
Regulatory category	OTC laxative
Primary commercial comparator	MiraLAX
Prescription requirement	No
Biosimilar relevance	None
Core formulation complexity	Low

PEG 3350 is a high-molecular-weight, water-soluble polymer that retains water in the stool. It is minimally absorbed and is used as the active pharmaceutical ingredient rather than as an inactive excipient.[1]

What excipients are used in Good Sense ClearLax?

Public product labeling for PEG 3350 powder products commonly identifies polyethylene glycol 3350 as the sole active ingredient and lists no inactive ingredients, or uses a very limited excipient system. The precise inactive-ingredient profile depends on the specific package, flavor, manufacturer, and National Drug Code.

The likely excipient strategy for an unflavored Good Sense ClearLax powder is therefore:

Formulation function	Likely approach
Active osmotic agent	PEG 3350
Diluent	Not required if the product is essentially neat PEG 3350 powder
Sweetener	Generally absent in unflavored products
Flavor	Absent or minimal in unflavored products
Colorant	Generally absent
Preservative	Not normally required for a dry powder
Glidant or flow aid	May be used at manufacturing level, subject to labeling requirements
Anti-caking system	May be addressed through particle engineering and packaging
Moisture control	High-barrier container and desiccant strategy, where needed

A product-specific excipient conclusion requires the applicable package label and inactive-ingredient statement. The central commercial point remains unchanged: Good Sense ClearLax does not appear to rely on a complex excipient platform comparable to a modified-release tablet, lipid formulation, or biologic delivery system.

How does the PEG 3350 formulation work?

PEG 3350 increases the water content of stool through an osmotic mechanism. The powder must disperse and dissolve sufficiently in the selected beverage to support consistent dosing and acceptable patient use.

The formulation targets are straightforward:

1. Maintain a consistent 17-gram dose.
2. Produce rapid wetting and dissolution.
3. Avoid visible clumping.
4. Minimize taste and mouthfeel.
5. Protect the powder from humidity.
6. Support accurate measuring or premeasured dosing.

Because PEG 3350 is the active ingredient, excipient changes can affect dissolution, dose uniformity, bulk density, flowability, hygroscopicity, and patient acceptance. A technically simple formula can still require process controls around particle size, blending, filling, and moisture exposure.

What excipient strategies could improve Good Sense ClearLax?

Flavor and taste-masking systems

The largest formulation opportunity is palatability. Unflavored PEG 3350 is typically mixed into water, juice, coffee, tea, or another beverage. Some patients perceive texture, residual sweetness, or a polymer-like mouthfeel.

Potential strategies include:

• Natural citrus or berry flavors.
• Low-intensity sweetener systems.
• Flavor encapsulation for improved stability.
• Effervescent or flavored drink-stick formats.
• pH adjustment to improve taste.
• Reduced residual mouthfeel through particle engineering.

Any flavor or sweetener addition would create new inactive ingredients and require stability, compatibility, labeling, and sensory evaluation. The product would also need to remain within the applicable OTC labeling framework.

Premeasured sachets and stick packs

A 17-gram stick pack can reduce dosing errors and improve portability. It may also support premium pricing over a bulk bottle.

Commercial benefits include:

• Better travel convenience.
• Lower risk of household measuring errors.
• Easier pharmacy and e-commerce fulfillment.
• Improved adherence for repeat users.
• Opportunity for multi-flavor packages.

The main constraints are packaging cost, powder fill accuracy, seal integrity, and moisture protection. Stick packs have greater packaging expense than a large bottle but can carry a higher retail price per dose.

Moisture-barrier packaging

PEG 3350 powders may cake or develop poor flow after humidity exposure. Packaging is therefore an important part of the product system.

Relevant options include:

• High-density polyethylene bottles with induction seals.
• Foil-laminate sachets.
• Desiccant-containing closures.
• Unit-dose blister or pouch systems.
• Child-resistant packaging where required by the product configuration.
• Tamper-evident seals.

Packaging improvements can be protected commercially through trade secrets, supplier know-how, and design rights even when the underlying formulation is not patentable.

Pediatric-oriented presentations

PEG 3350 is widely used in pediatric constipation management, but age-specific use and dosing require careful labeling and medical oversight. A commercial product could target caregivers through:

• Smaller unit-dose packets.
• Clear weight-based dosing instructions where legally permissible.
• Flavor options.
• Easy-dissolving powder.
• Calibrated dosing accessories.
• Educational packaging.

A pediatric product would face greater regulatory and safety scrutiny. It should not imply approval for a pediatric population beyond the applicable labeling.

Combination gastrointestinal products

A branded or private-label manufacturer could pair PEG 3350 with a complementary gastrointestinal product, such as:

• Electrolyte hydration products.
• Fiber supplements.
• Probiotic products.
• Stool-softening products.
• Digestive health powders.

These combinations create marketing opportunities but can complicate regulatory positioning. A product combining multiple active ingredients may not qualify for the same monograph pathway as a single-ingredient PEG 3350 laxative.

What FDA regulatory status applies to Good Sense ClearLax?

PEG 3350 laxative products are generally marketed under the FDA OTC laxative framework. The relevant regulatory standard identifies PEG 3350 as an osmotic laxative active ingredient and specifies the labeled use and dosing framework.[2]

Regulatory issue	Assessment
FDA OTC status	Consistent with OTC laxative regulation
NDA requirement	Generally not required for a compliant monograph product
ANDA pathway	Relevant only if the product is approved as a generic prescription or approved drug product rather than marketed under the OTC framework
Rx-to-OTC issue	Not central to current retail positioning
Labeling basis	OTC Drug Facts labeling and applicable monograph requirements
Clinical differentiation	Limited unless new claims or a new active combination is pursued
Postmarketing requirements	Standard OTC quality, complaint, adverse-event, and manufacturing controls

The product label typically warns against use for more than seven days without medical advice and identifies gastrointestinal and obstruction-related contraindication concerns.[1,2]

What is the Orange Book status of Good Sense ClearLax?

Good Sense ClearLax is not primarily an Orange Book-driven product. Orange Book listing is most relevant to approved new drugs, abbreviated new drug applications, and drug products with FDA approval records.[3]

A store-brand PEG 3350 product marketed under the OTC monograph system generally does not depend on Orange Book patent listings. As a result:

• There is typically no meaningful Orange Book patent estate associated with the retail product.
• Paragraph IV certification is generally not the central launch mechanism.
• Generic manufacturers do not need to challenge a branded PEG 3350 patent to enter the OTC monograph market.
• Market entry is driven by compliance, manufacturing economics, retailer access, and packaging differentiation.

The original MiraLAX product was developed as a drug product, but the commercial opportunity for store brands is based on the mature OTC category rather than on an active patent barrier. Current Orange Book records should be checked for any specific approved product and NDC before making a litigation or launch decision.[3]

When does Good Sense ClearLax lose exclusivity?

Good Sense ClearLax does not have meaningful drug exclusivity comparable to a recently approved prescription product. PEG 3350 is a mature active ingredient, and OTC monograph marketing does not ordinarily provide a fixed period of new-drug exclusivity.

Exclusivity type	Good Sense ClearLax assessment
New chemical entity exclusivity	None
Orphan exclusivity	None
Pediatric exclusivity	Not apparent for the retail product
OTC monograph exclusivity	None in the conventional NCE sense
Formulation exclusivity	Limited unless separately patented
Trademark exclusivity	Brand-specific and renewable
Trade-secret protection	Possible for manufacturing and packaging controls
Market exclusivity	Retailer, shelf-space, and distribution dependent

The primary legal protection is likely the Good Sense trademark and associated trade dress rather than an active pharmaceutical patent.

Are there Paragraph IV challenges or generic entry risks?

Paragraph IV challenges are unlikely to be commercially important for the Good Sense product itself. Paragraph IV litigation applies to patent certifications for products submitted through the ANDA process. A monograph-compliant OTC PEG 3350 product can generally be introduced without challenging a branded patent, provided it satisfies the applicable regulatory requirements.

Generic entry risks

Generic and private-label entry risk is high because:

• PEG 3350 is an established active ingredient.
• The dosage form is a conventional powder.
• Manufacturing technology is widely available.
• The product does not require a complex device.
• The OTC category has multiple retail channels.
• Consumers often view the product as interchangeable with other PEG 3350 products.

The main barriers are not molecule patents. They are:

• Reliable high-volume PEG sourcing.
• Powder flow and fill consistency.
• Moisture management.
• FDA-compliant labeling.
• Retailer approval.
• Product liability controls.
• Brand recognition and shelf placement.

What patents protect Good Sense ClearLax?

No core patent protection should be assumed for the PEG 3350 active ingredient or for the basic powder-for-solution dosage form. A company could seek patents for narrower improvements, including:

• A distinctive particle-size distribution.
• A low-caking powder composition.
• A flavor-masking system.
• A fast-dissolving granulation process.
• A moisture-resistant unit-dose package.
• A dosing device.
• A combination product.
• A new method of treating a specific constipation population.

Such patents would need meaningful novelty and non-obviousness. Broad claims covering PEG 3350 powder, oral laxative use, or routine flavors would face substantial validity risk because of the mature prior art.

Patent-strength assessment

Asset type	Expected strength
PEG 3350 composition of matter	Very weak or expired
Basic oral powder	Weak
Standard 17-gram dose	Weak
Flavor system	Moderate if technically distinctive
Particle-engineered powder	Moderate, claim dependent
Packaging system	Moderate
Dosing device	Moderate
Manufacturing process	Moderate to strong if difficult to replicate
Trademark and trade dress	Potentially meaningful
Retail distribution agreement	Commercially important but not patent protection

How strong is the commercial moat?

The commercial moat is modest. Good Sense ClearLax can compete through price and distribution but has limited technical differentiation.

Competitive advantages

• Retail private-label positioning.
• Familiar PEG 3350 active ingredient.
• Low ingredient cost.
• Broad consumer awareness of PEG laxatives.
• Compatibility with multiple beverages.
• Simple supply chain relative to liquid or tablet products.

Competitive weaknesses

• High substitution risk.
• Limited formulation differentiation.
• Strong competition from MiraLAX and other private labels.
• Low switching costs.
• Retail price transparency.
• Potential consumer sensitivity to product performance and taste.

The strongest commercial defense is a combination of retailer exclusivity, high in-stock performance, favorable unit economics, and a differentiated package format.

How does Good Sense ClearLax compare with MiraLAX?

Attribute	Good Sense ClearLax	MiraLAX
Active ingredient	PEG 3350	PEG 3350
Dosage form	Powder	Powder
Core mechanism	Osmotic laxative	Osmotic laxative
Primary positioning	Private-label or value	National brand
Price	Typically lower	Typically higher
Patent dependence	Limited	Legacy brand and formulation history
Consumer trust	Retailer dependent	National brand recognition
Differentiation	Price, access, package	Brand, advertising, recognition
Substitution risk	High	Moderate to high
Retail opportunity	Margin and private-label penetration	Premium brand economics

The active ingredient and basic administration method are substantially similar. The main difference is commercial positioning rather than pharmacology.

What licensing opportunities exist?

Licensing potential is limited for the basic PEG 3350 product because the active ingredient and dosage form are mature. More attractive opportunities include:

• Exclusive flavor technology.
• Licensed moisture-barrier packaging.
• Pediatric dosing systems.
• Unit-dose manufacturing platforms.
• E-commerce subscription packaging.
• Combination products with electrolyte or fiber systems.
• International private-label supply agreements.
• Contract manufacturing for regional pharmacy chains.

A licensing transaction would be more defensible if it transferred validated manufacturing know-how, regulatory documentation, packaging technology, or retailer access. A license covering only PEG 3350 powder would have limited negotiating value.

What revenue exposure does the product create?

Revenue exposure is primarily volume-driven. The product can generate predictable repeat sales, but margins are vulnerable to retailer pricing pressure and private-label competition.

Key commercial variables include:

• Number of retail doors.
• Average units per store per month.
• Pack size.
• Wholesale price.
• Gross margin after retailer discounts.
• Promotional frequency.
• E-commerce penetration.
• Seasonal constipation demand.
• Packaging cost per dose.
• PEG 3350 procurement cost.

A bulk bottle generally supports lower cost per dose and stronger value positioning. Single-dose packets can improve gross revenue per dose but increase packaging and filling costs. A tiered portfolio could include a value bottle, a premium stick pack, and a flavored variant.

What manufacturing and IP barriers matter most?

The principal manufacturing risks are operational rather than patent-based.

Manufacturing controls

A commercial manufacturer should control:

• PEG 3350 identity and molecular-weight specifications.
• Particle-size distribution.
• Bulk density.
• Moisture content.
• Flowability.
• Fill-weight accuracy.
• Dissolution or dispersion performance.
• Container-closure integrity.
• Microbiological quality.
• Stability under humidity and temperature stress.

The formulation is dry and relatively simple, but poor powder handling can cause inaccurate dosing, caking, slow dissolution, and customer complaints.

Geographic coverage

The U.S. opportunity is largely OTC and retail driven. International expansion may require separate review because PEG 3350 classification, approved claims, age restrictions, packaging rules, and monograph treatment vary by jurisdiction.

Potential markets include Canada, Europe, Latin America, and selected Asia-Pacific markets, but the regulatory basis cannot be assumed to transfer from the U.S. The product may be regulated as an OTC medicine, pharmacy medicine, food supplement, or prescription product depending on the country.

Key Takeaways

• Good Sense ClearLax is a PEG 3350 osmotic laxative powder with a low-complexity formulation.
• PEG 3350 is the active ingredient, not merely an excipient.
• The principal excipient opportunities are flavor, sweetener, particle engineering, moisture control, and unit-dose packaging.
• Patent protection for the basic product is likely weak; trademark, packaging, manufacturing know-how, and retail access are more important.
• Paragraph IV litigation and biosimilar risk are not central to the product.
• Generic and private-label entry risk is high because the active ingredient, dose, and dosage form are mature.
• The most credible commercial opportunities are stick packs, pediatric-oriented presentation, flavor differentiation, premium packaging, and retailer-exclusive supply.
• Manufacturing quality, dosing consistency, and moisture management are the main technical barriers.
• The product’s commercial moat depends on price, distribution, shelf placement, and consumer convenience rather than pharmaceutical exclusivity.

FAQs About Good Sense ClearLax

Is Good Sense ClearLax the same as MiraLAX?

Both products use PEG 3350 as the active ingredient and are used as osmotic laxatives. Differences may exist in package size, inactive ingredients, manufacturing source, labeling, and retail presentation.

Does Good Sense ClearLax contain preservatives?

A dry PEG 3350 powder generally does not require a conventional preservative system. The definitive answer depends on the inactive-ingredient statement for the specific NDC and package.

Can Good Sense ClearLax be reformulated as a flavored product?

Yes. A flavored version could use flavoring agents, sweeteners, acids, or other excipients, but the revised formula would require stability, sensory, labeling, and regulatory review.

Is PEG 3350 protected by an active U.S. patent?

The basic PEG 3350 laxative concept is mature and should not be treated as protected by a current composition-of-matter patent. Narrow patents could still apply to specific formulations, packaging, processes, or combination products.

Is Good Sense ClearLax a good candidate for private-label expansion?

Yes. Its simple OTC powder format, established active ingredient, and repeat-use category support private-label expansion. The strongest opportunities are retailer distribution, lower-cost bulk packaging, premeasured sachets, and differentiated flavor or convenience formats.

References

1. DailyMed. (n.d.). Polyethylene glycol 3350 powder, drug facts labeling. U.S. National Library of Medicine.
2. Code of Federal Regulations. (2024). 21 C.F.R. Part 334: Laxative drug products for over-the-counter human use. U.S. Food and Drug Administration.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
4. U.S. Food and Drug Administration. (2024). Over-the-counter drug review and monograph framework. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines